Literature DB >> 24457210

Elevated osteoprotegerin predicts declining renal function in elderly women: a 10-year prospective cohort study.

Joshua R Lewis1, Wai H Lim, Kun Zhu, Germaine Wong, Satvinder S Dhaliwal, Ee M Lim, Thor Ueland, Jens Bollerslev, Richard L Prince.   

Abstract

BACKGROUND: Elevated osteoprotegerin (OPG) levels are inversely correlated with creatinine clearance and end-stage renal disease in patients with diabetes, however its role in predicting decline in renal function and progression to a more advanced stage disease in the elderly general population is unknown.
METHODS: This was a prospective cohort study of 1,157 elderly women with serum OPG measured in 1998 and renal function estimated using serum creatinine and cystatin C-based estimated glomerular filtration rate (eGFR) at 5-yearly intervals. The primary objective of the study was to determine the relationship of circulating OPG levels with 5- and 10-year renal decline.
RESULTS: At baseline, participants with elevated OPG above the median (≥2.2 ng/ml) had a 5.0% lower CKD-EPI-creatinine and cystatin C eGFR compared to participants with lower OPG levels. In multivariable-adjusted linear regression models, elevated OPG levels at baseline were associated with greater 5- and 10-year decline in CKD-EPI-creatinine and cystatin C eGFR (-0.105, p = 0.002 and -0.104, p = 0.010, respectively). Elevated OPG at baseline was associated with increased 5- and 10-year risk of rapid renal decline (OR 2.13, 95% CI 1.33-3.43, p = 0.002 and OR 4.10, 95% CI 1.49-11.27, p = 0.006, respectively) and renal disease hospitalizations or deaths (HR 1.99, 95% CI 1.31-3.03, p = 0.001) after adjusting for known risk factors.
CONCLUSION: Elevated OPG levels are associated with long-term renal dysfunction and may be provide a useful biomarker to predict the trajectory of renal decline in older women.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24457210     DOI: 10.1159/000357787

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  13 in total

Review 1.  Proteomic biomarkers in kidney disease: issues in development and implementation.

Authors:  Harald Mischak; Christian Delles; Antonia Vlahou; Raymond Vanholder
Journal:  Nat Rev Nephrol       Date:  2015-02-03       Impact factor: 28.314

Review 2.  Osteoprotegerin and kidney disease.

Authors:  Alejandra Montañez-Barragán; Isaias Gómez-Barrera; Maria D Sanchez-Niño; Alvaro C Ucero; Liliana González-Espinoza; Alberto Ortiz
Journal:  J Nephrol       Date:  2014-04-23       Impact factor: 3.902

3.  Serum Osteoprotegerin Levels Related With Cardiovascular Risk Factors in Chronic Kidney Disease.

Authors:  Pinar Demir; Fusun Erdenen; Hale Aral; Turker Emre; Sennur Kose; Esma Altunoglu; Anil Dolgun; Berrin Bercik Inal; Aydin Turkmen
Journal:  J Clin Lab Anal       Date:  2016-03-17       Impact factor: 2.352

4.  Dietary inflammatory index and the aging kidney in older women: a 10-year prospective cohort study.

Authors:  Nicola P Bondonno; Lauren C Blekkenhorst; Anna L Bird; Joshua R Lewis; Jonathan M Hodgson; Nitin Shivappa; James R Hébert; Richard J Woodman; Germaine Wong; Deborah A Kerr; Wai H Lim; Richard L Prince
Journal:  Eur J Nutr       Date:  2019-12-11       Impact factor: 5.614

5.  Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients.

Authors:  Stella Bernardi; Barbara Toffoli; Fleur Bossi; Riccardo Candido; Elisabetta Stenner; Renzo Carretta; Fabio Barbone; Bruno Fabris
Journal:  BMC Nephrol       Date:  2017-07-06       Impact factor: 2.388

6.  Serum osteoprotegerin and renal function in the general population: the Tromsø Study.

Authors:  Anders Vik; Ellen E Brodin; Ellisiv B Mathiesen; Jan Brox; Lone Jørgensen; Inger Njølstad; Sigrid K Brækkan; John-Bjarne Hansen
Journal:  Clin Kidney J       Date:  2016-10-03

Review 7.  TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?

Authors:  Stella Bernardi; Rebecca Voltan; Erika Rimondi; Elisabetta Melloni; Daniela Milani; Carlo Cervellati; Donato Gemmati; Claudio Celeghini; Paola Secchiero; Giorgio Zauli; Veronica Tisato
Journal:  Clin Sci (Lond)       Date:  2019-05-16       Impact factor: 6.124

8.  Elevated Circulating Osteoprotegerin and Renal Dysfunction Predict 15-Year Cardiovascular and All-Cause Mortality: A Prospective Study of Elderly Women.

Authors:  Joshua R Lewis; Wai H Lim; Thor Ueland; Germaine Wong; Kun Zhu; Ee M Lim; Jens Bollerslev; Richard L Prince
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

Review 9.  Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease.

Authors:  Stella Bernardi; Fleur Bossi; Barbara Toffoli; Bruno Fabris
Journal:  Biomed Res Int       Date:  2016-04-21       Impact factor: 3.411

10.  Circulating Osteoprotegerin in Chronic Kidney Disease and All-Cause Mortality.

Authors:  Joanna Kamińska; Marek Stopiński; Krzysztof Mucha; Michał Pac; Marek Gołębiowski; Monika A Niewczas; Leszek Pączek; Bartosz Foroncewicz
Journal:  Int J Gen Med       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.